文献速递白血病造血干细胞移植与细胞治疗

高危Ph阴性成人ALL:化疗或异基因移植

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
PubMed 文献 · Blood · 2021-01-01

ALL-HR-11试验评估高危Ph阴性成人ALL依据诱导和巩固后MRD水平分配化疗或allo-HSCT的结局。全组5年CIR 43%±7%、OS 49%±7%、EFS 40%±6%;化疗组CIR 45%±8%、OS 59%±9%,allo-HSCT组CIR 40%±12%、OS 38%±11%。避免allo-HSCT不损害MRD应答充分患者结局。

要点

  • 诱导后MRD<0.1%且早期巩固后<0.01%者分配延迟巩固和维持治疗至CR 2年。
  • 其余患者分配allo-HSCT;按意向治疗化疗218例、allo-HSCT 106例。
  • MRD清除不佳者尤其需要更好的缓解后替代治疗。

核心结论

  • 避免allo-HSCT不损害≤60岁、诱导和巩固后MRD应答充分的高危Ph阴性成人ALL患者结局。
  • MRD清除不佳患者尤其需要更好的缓解后替代治疗。

研究设计与样本

  • ALL-HR-11试验纳入15至60岁高危Ph阴性ALL完全缓解患者。
  • MRD由8色流式细胞术中心评估,依据诱导和巩固后MRD水平分配化疗或allo-HSCT。
  • 348例中315例达CR(91%),289例中220例诱导后MRD<0.1%(76%)。
  • 按意向治疗218例分配化疗、106例分配allo-HSCT。

主要发现

  • 全组5年CIR为43%±7%,OS为49%±7%,EFS为40%±6%。
  • 化疗组5年CIR为45%±8%,OS为59%±9%。
  • allo-HSCT组5年CIR为40%±12%,OS为38%±11%。

关键数值与推荐

  • 诱导后MRD<0.1%且早期巩固后MRD<0.01%者接受延迟巩固和维持治疗至CR 2年。
  • 其余患者分配allo-HSCT。

临床怎么用

  • 对≤60岁高危Ph阴性成人ALL,可依据诱导和巩固后MRD水平决定是否避免allo-HSCT。
  • MRD应答充分者可接受化疗为主的延迟巩固和维持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) with high-risk (HR) features and adequate measurable residual disease (MRD) clearance remains unclear. The aim of the ALL-HR-11 trial was to evaluate the outcomes of HR Ph- adult ALL patients following chemotherapy or allo-HSCT administered based on end-induction and consolidation MRD levels. Patients aged 15 to 60 years with HR-ALL in complete response (CR) and MRD levels (centrally assessed by 8-color flow cytometry) <0.1% after induction and <0.01% after early consolidation were assigned to receive delayed consolidation and maintenance therapy up to 2 years in CR. The remaining patients were allocated to allo-HSCT. CR was attained in 315/348 patients (91%), with MRD <0.1% after induction in 220/289 patients (76%). By intention-to-treat, 218 patients were assigned to chemotherapy and 106 to allo-HSCT. The 5-year (±95% confidence interval) cumulative incidence of relapse (CIR), overall survival (OS), and event-free survival probabilities for the whole series were 43% ± 7%, 49% ± 7%, and 40% ± 6%, respectively, with CIR and OS rates of 45% ± 8% and 59% ± 9% for patients assigned to chemotherapy and of 40% ± 12% and 38% ± 11% for those assigned to allo-HSCT, respectively. Our results show that avoiding allo-HSCT does not hamper the outcomes of HR Ph- adult ALL patients up to 60 years with adequate MRD response after induction and consolidation. Better postremission alternative therapies are especially needed for patients with poor MRD clearance. This trial was registered at www.clinicaltrials.gov as # NCT01540812.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ribera JM, Morgades M, Ciudad J, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021. PMID: 33150388. doi:10.1182/blood.2020007311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。